Lunit Submits 16 Abstracts to ASCO, the Most Among AI Companies

Medical AI company Lunit announced on the 8th that it will present 16 research abstracts at the 2023 American Society of Clinical Oncology (ASCO 2023), held in Chicago, USA, from the 2nd to the 6th of next month. The adoption of 16 research abstracts is the highest number among global medical AI companies participating in ASCO 2023 and domestic companies attending the conference.

Lunit's AI biomarker platform 'Lunit Scope IO (left)' and AI pathology analysis solution 'Lunit Scope PD-L1'
[Photo by Lunit]

ASCO, established in 1964, is one of the world's top three cancer societies, attended annually by more than 40,000 medical professionals. Lunit has been presenting its latest research at ASCO every year since 2019. Following the adoption of 11 abstracts last year, it will present the largest number of 16 research results this year as well.

At ASCO 2023, Lunit plans to present various independent and collaborative studies related to its AI biomarker, Lunit Scope. First, Lunit will announce results measuring changes in tumor-infiltrating lymphocytes (TILs), immune cells, by applying its AI-based biomarker Lunit Scope to pathological tissues of patients with locally advanced rectal cancer (LARC) undergoing chemoradiotherapy (CRT). This study was conducted in collaboration with the National Cancer Center East Hospital of Japan, one of the top cancer specialty hospitals in Japan, enhancing the reliability of the research.

Additionally, results will be presented from a study investigating immune cell changes by applying Lunit Scope before and after combination immunotherapy with durvalumab (brand name Imfinzi) and tremelimumab in patients with head and neck squamous cell carcinoma (SCC), conducted as a domestic researcher-led clinical trial. Furthermore, findings confirming immune responses through Lunit Scope after triple therapy including pembrolizumab (brand name Keytruda) in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma patients will also be disclosed.

Moreover, a study led by the world-renowned Mayo Clinic in the United States will be presented, applying Lunit Scope’s three immune phenotypes?immune active, immune excluded, and immune deficient?classified according to patients’ immunological profiles, to stage III colorectal cancer patients. In addition, results analyzing cancer tissues from the U.S. National Institutes of Health big data (TCGA) using Lunit Scope, as well as predictions of MET mutations in non-small cell lung cancer (NSCLC) utilizing Lunit Scope, will be revealed.

Furthermore, results investigating the expression of various target proteins across multiple cancer types using Lunit Scope uIHC, an AI-based immunohistochemistry analysis model, will be introduced. uIHC also attracted attention when presented at the American Association for Cancer Research (AACR 2023) held last month.

Seobum Seok, CEO of Lunit, said, "At ASCO 2023 this year, Lunit will present a large number of research results applying the AI biomarker platform Lunit Scope across various fields. Through the largest number of abstract presentations ever, we have clearly demonstrated that Lunit Scope can be used not only to predict treatment responses to immunotherapy but also for monitoring progress, analyzing the tumor microenvironment, and predicting genomic information."

This content was produced with the assistance of AI translation services.